LIVZON PHARMAC. GRP H YC1 Working Capital to Net Assets Ratio
LIVZON PHARMAC. GRP H YC1 working capital to net assets ratio. LIVZON PHARMAC. GRP H YC1 (LP6) has a Working Capital to Net Assets ratio of 49.2% as of March 2026. Working capital of €7.67 Billion (current assets of €15.66 Billion minus current liabilities of €7.99 Billion) is measured against net assets of €15.58 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible equity quality of LIVZON PHARMAC. GRP H YC1 to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of LIVZON PHARMAC. GRP H YC1 (2021–2025)
Working capital to net assets ratio of LIVZON PHARMAC. GRP H YC1 from 2021 to 2025. This chart shows how LIVZON PHARMAC. GRP H YC1's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of March 2026, the ratio stands at 49.2%, reflecting working capital of €7.67 Billion against net assets of €15.58 Billion EUR. See LP6 days of operational coverage to measure how many days the company can operate on defensive assets alone.
LIVZON PHARMAC. GRP H YC1 Working Capital to Net Assets Ratio by Year (2021–2025)
LIVZON PHARMAC. GRP H YC1 working capital to net assets ratio by year from 2021 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for LIVZON PHARMAC. GRP H YC1 from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see LP6 total assets.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 57.2% | €8.90 Billion | €15.55 Billion | €16.12 Billion | €7.22 Billion | ▼ -1.8 pp |
| 2024 | 59.0% | €8.79 Billion | €14.91 Billion | €16.42 Billion | €7.63 Billion | ▼ -3.2 pp |
| 2023 | 62.2% | €9.18 Billion | €14.77 Billion | €17.27 Billion | €8.09 Billion | ▼ -2.0 pp |
| 2022 | 64.2% | €9.59 Billion | €14.94 Billion | €16.99 Billion | €7.40 Billion | ▲ +10.1 pp |
| 2021 | 54.1% | €7.75 Billion | €14.31 Billion | €14.67 Billion | €6.93 Billion | — |